Study guide

9.2 Inhaled Nitric Oxide: Toxicity, Monitoring & Weaning

NBRC RRT-NPS Neonatal/Pediatric Specialist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Neonatal and Pediatric Patient Assessment

1.1 Maternal, Obstetric & Perinatal History 1.2 Fetal Surveillance & Antepartum Diagnostics 1.3 Gestational Age & Baseline Neonatal Examination 1.4 Apgar, Respiratory Distress & Thoracic Assessment 1.5 Pediatric Assessment Triangle & Vital Signs 1.6 Neurologic Assessment, Respiratory Failure & Triage

2 Chapter 2: Diagnostic Evaluation & Gas Exchange Monitoring

2.1 Pulse Oximetry, Pre/Postductal & Transcutaneous Monitoring 2.2 Capnography, Waveforms & Dead-Space Evaluation 2.3 Arterial & Capillary Blood-Gas Sampling 2.4 Umbilical Lines, Acid-Base & Laboratory Evaluation 2.5 Chest Imaging & Airway Radiography 2.6 Pulmonary Function, Bronchoscopy & Specimen Diagnostics

3 Chapter 3: Airway Management & Secretion Clearance

3.1 Pediatric Airway Anatomy & ETT Sizing 3.2 Cuffed Airways, Intubation & Difficult-Airway Management 3.3 Tracheostomy Devices & Routine Care 3.4 Tracheostomy Emergencies, Speaking & Decannulation 3.5 Airway Suctioning Technique & Safety 3.6 Airway Clearance, Home Care & Discharge Planning

4 Chapter 4: Pharmacology & Medical Gas Therapy

4.1 Aerosol Physics & Delivery Devices 4.2 Respiratory & Systemic Pharmacology 4.3 Oxygen Interfaces & Delivery Systems 4.4 Oxygen Blenders, Targets & Toxicity 4.5 HFNC Physiology, Sizing & Flow 4.6 HFNC Indications, Monitoring & Escalation

5 Chapter 5: Shared Neonatal & Pediatric Pulmonary Disorders

5.1 Neonatal RDS Pathophysiology & Management 5.2 TTN, Pneumonia & the Neonatal Differential 5.3 Meconium Aspiration & PPHN 5.4 BPD, Apnea & Chronic Neonatal Lung Disease 5.5 Bronchiolitis, Croup & Epiglottitis 5.6 Asthma, Cystic Fibrosis & Foreign-Body Aspiration

6 Chapter 6: Resuscitation, Emergency Protocols & Patient Safety

6.1 NRP Cord Management, Initial Steps & Ventilation 6.2 NRP Corrective Steps, Compressions & Medications 6.3 PALS Assessment, CPR & Cardiac Arrest 6.4 PALS Dysrhythmia & Shock Management 6.5 Neonatal & Pediatric Transport 6.6 Patient Safety, Teamwork & Family-Centered Care

7 Chapter 7: Noninvasive & Conventional Mechanical Ventilation

7.1 Bubble CPAP & Neonatal NIV 7.2 Pediatric NIV, Interfaces & Failure Recognition 7.3 Conventional Ventilation Physics & Modes 7.4 Initial Settings & ABG-Guided Titration 7.5 Ventilator Scalars & Loops 7.6 Ventilator Dyssynchrony & Troubleshooting 7.7 Weaning Readiness & Spontaneous Breathing Trials 7.8 Extubation & Post-Extubation Airway Risk

8 Chapter 8: High-Frequency Ventilation & Advanced Modes

8.1 HFOV Mechanics & Gas Transport 8.2 HFOV Controls & Clinical Management 8.3 HFJV Circuit & Controls 8.4 HFJV Servo Pressure & Clinical Indications 8.5 NAVA, Edi & Proportional Support 8.6 APRV in Pediatric Respiratory Failure

9 Chapter 9: Specialty Inhaled Gases & Exogenous Surfactant Therapy

9.1 Inhaled Nitric Oxide: Mechanism, Indications & Dose 9.2 Inhaled Nitric Oxide: Toxicity, Monitoring & Weaning 9.3 Heliox Physics & Delivery 9.4 Volatile Anesthetic & Subambient Gas Therapy 9.5 Surfactant Biology, Products & Dosing 9.6 Surfactant Administration & Response

10 Chapter 10: Pediatric ARDS & Parenchymal Critical Illness

10.1 PALICC-2 Diagnosis & Severity 10.2 PALICC-2 NIV & Possible PARDS 10.3 PARDS Lung-Protective Ventilation 10.4 PARDS Refractory Hypoxemia & Adjuncts 10.5 PIE & Pneumothorax Recognition 10.6 Thoracic Decompression & Chest Drains

11 Chapter 11: Congenital Heart Disease & Hemodynamic Management

11.1 Left-to-Right Shunts & Qp/Qs Physiology 11.2 Acyanotic Lesions & Respiratory Management 11.3 Cyanotic Lesions & the Five Ts 11.4 Ductal Dependence, PGE1 & the Hyperoxia Test 11.5 Single-Ventricle Physiology & Staged Palliation 11.6 Gas Balancing, Hemodynamics & NIRS

12 Chapter 12: Advanced Critical Care: ECMO, Neurotrauma & Palliative Care

12.1 ECMO Candidacy & Modality 12.2 ECMO Circuit, Lung Rest & Anticoagulation 12.3 Neurotrauma, ICP & Ventilation 12.4 Neonatal Therapeutic Hypothermia & Respiratory Care 12.5 Death by Neurologic Criteria: Examination & Apnea Testing 12.6 DNC Timing, Ancillary Testing, Palliation & Donation

9.2 Inhaled Nitric Oxide: Toxicity, Monitoring & Weaning

Key Takeaways Explain This Topic AI

Use a calibrated cleared delivery system with continuous inspired NO, inspired NO2, and FiO2 monitoring plus backup delivery capability. Measure methemoglobin within 4-8 hours after starting iNO and periodically thereafter, then respond using the drug label, device manual, and unit protocol.

Avoid abrupt iNO discontinuation. Wean in several steps with pauses and close oxygenation/hemodynamic observation; if rebound occurs, reinstate the prior effective dose and support oxygenation while reassessing the disease and delivery system.

The INOmax label directs delivery-system assessment and analyzer recalibration when inspired nitrogen dioxide reaches 3 ppm in the circuit; individual device alarm limits may be set lower.

Escalating beyond the recommended 20 ppm neonatal dose is not routine for nonresponders because higher doses raise nitrogen dioxide and methemoglobin exposure without demonstrated added benefit.

Last updated: September 2026

  • 9.2 Inhaled Nitric Oxide: Toxicity, Monitoring & Weaning
  • Toxic Byproducts & Critical Safety Monitoring

Inhaled nitric oxide carries the risk of significant biochemical toxicities. Strict continuous monitoring and serial laboratory evaluations are mandatory.

Monitoring the Two Principal Toxic Exposures

Hazard Why it occurs Required surveillance Response

Nitrogen dioxide ( N O 2 NO_2 N O 2 ​ ) NO reacts with oxygen; generation rises with NO concentration, oxygen concentration, and contact time Continuously monitor inspired N O 2 NO_2 N O 2 ​ at the location specified by the cleared delivery system. The INOmax label directs system assessment and analyzer recalibration for an unexpected change or a circuit concentration reaching 3 ppm. Device alarm limits may be lower. Check injector and sampling setup, calibrate and troubleshoot per the device manual, and adjust iNO or F i O 2 FiO_2 F i O 2 ​ as clinically appropriate. Do not improvise injector placement.

Methemoglobin ( M e t H b MetHb M e t H b ) NO oxidizes hemoglobin iron, reducing oxygen-carrying capacity Measure within 4-8 hours after initiation and periodically throughout treatment; check sooner after a dose change or when unexplained hypoxemia or saturation discrepancy occurs according to protocol. Reduce or discontinue iNO when clinically important elevation occurs. If it does not resolve, toxicology/neonatal experts select additional treatment such as vitamin C, methylene blue, or transfusion based on severity and contraindications.

Delivery-System Safety

Use only a compatible calibrated delivery system and place the injector and sampling line exactly as its operating manual specifies.

Continuously display delivered NO, inspired N O 2 NO_2 N O 2 ​ , and F i O 2 FiO_2 F i O 2 ​ ; keep backup power and an independent reserve delivery system available.

Trend oxygenation, blood pressure, perfusion, pulmonary pressure, and ventricular function. Systemic hypotension or new pulmonary edema requires immediate reassessment.

Stepwise Weaning Protocol & Preventing Rebound Pulmonary Hypertension

Abrupt discontinuation can cause rebound pulmonary hypertension with worsening oxygenation, hypotension, bradycardia, or low cardiac output and must be avoided. [Clinical improvement and an explicit weaning order]

  • |
  • v
  • [Reduce iNO in several protocol-defined steps]
  • |
  • v
  • [Pause at each step; observe SpO2, FiO2, pressure, perfusion and echo data]
  • |
  • stable? --+-- no --> [Return to prior effective dose and reassess]
  • |
  • yes
  • v
  • [Discontinue from a low dose with bedside observation and prescribed oxygen]
  • The Pathophysiology of Rebound PPHN

Abrupt withdrawal can cause rebound pulmonary vasoconstriction and hypoxemia through loss of the inhaled vasodilator and altered endogenous signaling. The response ranges from modest desaturation to severe pulmonary-hypertension and right-ventricular decompensation, especially when disease remains active. Prevent it with staged weaning and immediate monitoring.

Weaning Execution Rules

Wean in protocol-defined steps only after lung disease, hemodynamics, and pulmonary hypertension are improving.

Many neonatal pathways taper to a low dose such as 1 ppm before discontinuation, watching saturation, OI, pressure, and right-ventricular function after every step. Dwell time varies.

Some protocols temporarily adjust FiO2 around final discontinuation. Avoid an automatic 10%–20% increase; use the lowest oxygen needed for the prescribed target and reverse the prior iNO step promptly if rebound occurs.

  • Worked Clinical Calculation: Oxygenation Index & iNO Response
  • Clinical Scenario

A 39-week gestational age male infant weighing 3.6 kg 3.6\text{ kg} 3.6 kg is delivered via emergency cesarean section for meconium aspiration syndrome. The infant is intubated and mechanically ventilated in Pressure-Regulated Volume Control (PRVC) mode with the following parameters:

  • Fraction of Inspired Oxygen ( F i O 2 FiO_2 F i O 2 ​ ): 1.00 1.00 1.00 ( 100 % 100\% 100% )
  • Mean Airway Pressure ( P a w Paw P a w ): 18 cmH 2 O 18\text{ cmH}_2\text{O} 18 cmH 2 ​ O

Arterial Blood Gas ( A B G ABG A BG ): p H 7.24 pH\text{ }7.24 p H 7.24 , P a C O 2 52 mmHg PaCO_2\text{ }52\text{ mmHg} P a C O 2 ​ 52 mmHg , P a O 2 42 mmHg PaO_2\text{ }42\text{ mmHg} P a O 2 ​ 42 mmHg , H C O 3 − 22 mEq/L HCO_3^-\text{ }22\text{ mEq/L} H C O 3 − ​ 22 mEq/L , B E − 4 mEq/L BE\text{ }-4\text{ mEq/L} BE − 4 mEq/L

Echocardiogram reveals suprasystemic right ventricular pressures with a right-to-left shunt across the ductus arteriosus.

Step-by-Step Clinical Calculation

Calculate Baseline Oxygenation Index (OI): OI = P a w × F i O 2 × 100 P a O 2 = 18 × 1.00 × 100 42 = 1800 42 ≈ 42.9 \text{OI} = \frac{Paw \times FiO_2 \times 100}{PaO_2} = \frac{18 \times 1.00 \times 100}{42} = \frac{1800}{42} \approx \mathbf{42.9} OI = P a O 2 ​ P a w × F i O 2 ​ × 100 ​ = 42 18 × 1.00 × 100 ​ = 42 1800 ​ ≈ 42.9

Interpretation: The OI of 42.9 confirms severe hypoxemic respiratory failure. The echocardiogram—not OI alone—establishes pulmonary-hypertension physiology. This high and worsening severity warrants an iNO trial under the neonatal protocol and urgent ECMO-center consultation; it does not make either therapy automatic.

Initiate Therapy:

Initiate inhaled nitric oxide at 20 ppm 20\text{ ppm} 20 ppm .

Set saturation targets and alarms from the infant's prescription and diagnosis.

Verify calibrated NO, N O 2 NO_2 N O 2 ​ , and F i O 2 FiO_2 F i O 2 ​ monitoring and set device alarms according to the cleared system and unit protocol.

Assess Post-Initiation ABG (30 Minutes Post-iNO):

Post-treatment parameters: F i O 2 1.00 FiO_2\text{ }1.00 F i O 2 ​ 1.00 , P a w 18 cmH 2 O Paw\text{ }18\text{ cmH}_2\text{O} P a w 18 cmH 2 ​ O , P a O 2 110 mmHg PaO_2\text{ }110\text{ mmHg} P a O 2 ​ 110 mmHg .

Calculate Post-Treatment OI: OI post = 18 × 1.00 × 100 110 = 1800 110 ≈ 16.4 \text{OI}_{\text{post}} = \frac{18 \times 1.00 \times 100}{110} = \frac{1800}{110} \approx \mathbf{16.4} OI post ​ = 110 18 × 1.00 × 100 ​ = 110 1800 ​ ≈ 16.4

Response Analysis:

Increase in P a O 2 = 110 − 42 = + 68 mmHg PaO_2 = 110 - 42 = +68\text{ mmHg} P a O 2 ​ = 110 − 42 = + 68 mmHg ( > 20 mmHg > 20\text{ mmHg} > 20 mmHg threshold).

Percent reduction in OI = 42.9 − 16.4 42.9 × 100 % = 61.8 % \text{OI} = \frac{42.9 - 16.4}{42.9} \times 100\% = 61.8\% OI = 42.9 42.9 − 16.4 ​ × 100% = 61.8% ( > 33 % > 33\% > 33% threshold).

Conclusion: This is a strong acute oxygenation response at unchanged support. Continue to trend the response and the underlying disease; improvement does not by itself cancel ECMO-center planning. Measure methemoglobin within 4-8 hours and periodically thereafter.

NPS Exam Traps

Warning

Exam Trap 1: The "More is Better" Dosing Fallacy

If an infant does not respond to the recommended 20 ppm neonatal dose, routine escalation to 40 or 80 ppm is not recommended: higher doses increase N O 2 NO_2 N O 2 ​ and methemoglobin exposure without demonstrated additional benefit. Verify delivery, lung recruitment, anatomy, ventricular function, and diagnosis, and activate the appropriate rescue pathway.

Exam Trap 2: Methylene Blue in G6PD Deficiency

Methylene blue requires caution or avoidance in known G6PD deficiency because response may be poor and hemolysis can occur. Reduce or stop the oxidant exposure first, support oxygen delivery, and obtain neonatal/toxicology direction for vitamin C, methylene blue, or transfusion rather than selecting treatment from ancestry.

Exam Trap 3: Rebound PPHN from Rapid Weaning

If severe hypoxemia and hypotension begin immediately after abrupt iNO discontinuation, reinstate the prior effective dose, support oxygenation and ventilation to prescribed targets, verify delivery, and treat hemodynamic instability while the team reassesses. A fixed F i O 2 FiO_2 F i O 2 ​ of 1.00 is not mandatory when a lower concentration promptly meets the target.